Full Press Release Details
ASX/NASDAQ Announcement
Immuron Double Digit 3Q Sales
Sales Highlights (unaudited):
Melbourne, Australia, 17 April
2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce
continued sales growth (unaudited) of Travelan , an over-the-counter immune supplement that targets pathogenic bacteria and the toxins
they produce in the gastrointestinal (GI) tract.
Continued Travelan Q3 sales
growth (+15% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital
and social media marketing. (2) same store growth as a result of increased promotion and past promotions driving new customers and return
customers respectively; (3) growth from new stores within banner groups in which we secured core ranging in FY25; (4) increased South
Q3 sales in the U.S. increased
(+1% on pcp) on the back on number of marketing initiatives including: (1) improved Travelan store on Amazon.com;
(2) local U.S. Travelan Facebook and Instagram pages; (3) increased paid social, influencer and organic social media marketing.
These growth factors were offset by the impact of the Australian dollar strengthening against the US dollar.
During FY25 we had a Q1 pipeline
fill into over a thousand Canada retail doors on the back of securing listings within key pharmacy and grocery retail groups. We previously
reported that sales picked up on the back of consumer promotions in Q2 FY26 (+191% on prior quarter). As anticipated, there
was a continued increase in pull through from stores as we continue to build Travelan brand awareness within Canada though our in-store
educational programs, in-store promotions, and social media marketing as well as initial sales to Jean Coutu, the leading pharmacy group
in Quebec, the second largest province in Canada by population. Sales in Q3 FY26 grew 82% on the prior quarter.
This release has been authorised by the Directors of Immuron
Chief Executive Officer
Travelan is an orally administered
passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder
that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a purified tablet preparation of hyper-immune
bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology
associated with traveler's diarrhea. In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic
Goods (AUST L 106709) and is indicated to reduce the risk of Traveler's Diarrhea, reduce the risk of minor gastro-intestinal disorders
and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk
of Traveler's Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.
Immuron Limited (ASX: IMC, NASDAQ:
IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies
for the treatment of inflammatory mediated and infectious diseases.
Immuron Platform Technology
Immuron's proprietary technology
is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing
highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment
of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses
this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying
nature of Immuron's platform technology enables the development of medicines across a large range of infectious diseases. The platform
can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
For more information visit: https://www.immuron.com.au/
Sign up to Immuron's Investor
FORWARD-LOOKING STATEMENTS:
This press release may contain
"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy
and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks
relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships;
risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate
and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any
change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required